Loading...
Market
Increase in survival rates in human trials with AI antivenoms by end of 2026?
2
Resolution / Starting Odds
0-10% increase • 25%
11-20% increase • 25%
21-30% increase • 25%
More than 30% increase • 25%
Published results from human clinical trials
Story
AI-Designed Proteins Neutralize Snake Venom Toxins, Achieving 80-100% Survival Rates in Mice Tests on January 15 by David Baker
Jan 15, 2025, 02:00 PM
Researchers have successfully utilized artificial intelligence (AI) to design proteins that can neutralize toxins from snake venom, a breakthrough that could lead to the development of more effective and safer antivenoms. A study published on January 15 in the journal Nature, led by Nobel Laureate David Baker's team, demonstrated that these AI-designed proteins achieved survival rates of 80-100% in tests conducted on mice. This innovative approach not only offers a faster and cheaper method for creating antivenoms but also addresses the urgent need for improved treatments for snakebite envenoming, which poses a significant public health challenge globally. The research highlights the potential of generative AI in drug development, particularly in the design of therapeutic proteins against neglected tropical diseases.
View original story
Similar markets
11-15 species • 25%
1-5 species • 25%
6-10 species • 25%
More than 15 species • 25%
South America • 25%
Africa • 25%
Asia • 25%
North America • 25%
Yes • 50%
No • 50%
No significant effect on lifespan • 25%
Proven effective with significant lifespan extension • 25%
Negative effects or halted trials • 25%
Proven effective with moderate lifespan extension • 25%
No • 50%
Yes • 50%
Efficacy below 50% • 25%
Efficacy between 75% and 90% • 25%
Efficacy between 50% and 75% • 25%
Efficacy above 90% • 25%